Related Experiment Video
Updated: Aug 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Different types of interferon for the therapy of HCV chronic active hepatitis in the elderly patient
1Department of Geriatrics and Gerontology, University of Catania, Italy.
Insights
Hepatitis C virus (HCV) correlated hepatitis in older adults shows recombinant interferon alpha is the most effective treatment. Despite potential side effects, its higher remission rate makes it the preferred choice for elderly patients.
Area of Science:
- Hepatology
- Virology
- Geriatric Medicine
Background:
- Hepatitis C virus (HCV) correlated hepatitis is increasingly prevalent in individuals over 60.
- Current treatment options for this demographic are limited, primarily involving interferon therapy.
Purpose of the Study:
- To compare the efficacy and safety of three interferon types for treating HCV-correlated chronic hepatitis in the elderly.
- To determine the optimal interferon therapy for older patients based on remission rates and side effect profiles.
Main Methods:
- Review and analysis of three previous studies involving recombinant interferon alpha, interferon beta, and lymphoblastoid interferon.
- Evaluation of patient remission percentages and reported side effects in elderly populations.
Main Results:
- Recombinant interferon alpha demonstrated the highest remission rate at 75%.
- Interferon beta achieved a 53.8% remission rate, while lymphoblastoid interferon showed 60%.
- Beta-interferon exhibited minimal side effects in elderly patients.
Conclusions:
- Recombinant interferon alpha is the preferred treatment for HCV-correlated chronic hepatitis in the elderly due to superior efficacy.
- Despite a potentially higher risk of side effects, the risk/benefit ratio favors recombinant interferon alpha for this patient group.
Abstract:
HCV correlated hepatitis is a pathology on the increase, and it is especially affecting patients above 60 years old. The only treatment for this disease is therapy with different types of interferon. The authors take into examination three of their previous studies on treatment of HCV correlated chronic hepatitis in the elderly using different types of interferon: recombinant interferon alpha, interferon beta, and lymphoblastoid interferon, in order to evaluate which one, among the three, should be the best for the treatment of this pathology in the elderly. The data show that recombinant interferon alpha is preferable since the remission percentage is higher (75%), compared to beta (53.8%) and lymphoblastoid interferon (60%). As far as the relevant side-effects in elderly patients are concerned, beta-interferon therapy is almost with no side-effects. Even in cases where there could be a possible higher exposure to side-effects linked to the use of recombinant interferon alpha, still, the risk/benefit ratio suggests that this particular drug should be used for treating this pathology in elderly patients.
More Related Videos
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatitis
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction